Literature DB >> 21983328

How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs.

Fabrizio Marcucci1, Angelo Corti.   

Abstract

Solid tumors are characterized by an abnormal architecture and composition that limit the uptake and distribution of antitumor drugs. Over the last two decades, drugs have been identified that improve the tumor uptake and distribution of drugs that have direct antitumor effects. We propose to refer to these drugs as promoter drugs, and as effector drugs to drugs that have direct antitumor effects. Some promoter drugs have received regulatory approval, while others are in active clinical development. This review gives an overview of promoter drugs, by classifying them according to their mechanism of action: promoter drugs that modulate tumor blood flow, modify the barrier function of tumor vessels, induce tumor cell killing, and overcome stromal barriers. Eventually, we discuss those that we feel are the main conclusions to be drawn from promoter drug research that has been performed so far, and suggest areas of future investigation to improve the efficacy of promoter drugs in cancer therapy. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983328     DOI: 10.1016/j.addr.2011.09.007

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  30 in total

1.  Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment.

Authors:  Liliana Guzman-Rojas; Roberto Rangel; Ahmad Salameh; Julianna K Edwards; Eleonora Dondossola; Yun-Gon Kim; Alan Saghatelian; Ricardo J Giordano; Mikhail G Kolonin; Fernanda I Staquicini; Erkki Koivunen; Richard L Sidman; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  Early imaging marker of progressing glioblastoma: a window of opportunity.

Authors:  Na Tosha N Gatson; Shane P Bross; Yazmin Odia; Gino J Mongelluzzo; Yirui Hu; Laura Lockard; Jesse J Manikowski; Anand Mahadevan; Syed A J Kazmi; Michel Lacroix; Andrew R Conger; Joseph Vadakara; Lakshmi Nayak; T Linda Chi; Minesh P Mehta; Vinay K Puduvalli
Journal:  J Neurooncol       Date:  2020-06-29       Impact factor: 4.130

Review 3.  Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.

Authors:  Fabrizio Marcucci; Matteo Bellone; Cristiano Rumio; Angelo Corti
Journal:  MAbs       Date:  2012-12-04       Impact factor: 5.857

Review 4.  Chromogranin A and derived peptides in health and disease.

Authors:  Y Peng Loh; Yong Cheng; Sushil K Mahata; Angelo Corti; Bruno Tota
Journal:  J Mol Neurosci       Date:  2012-03-03       Impact factor: 3.444

5.  A Multilayered Cell Culture Model for Transport Study in Solid Tumors: Evaluation of Tissue Penetration of Polyethyleneimine Based Cationic Micelles.

Authors:  Seiji Miura; Hidenori Suzuki; You Han Bae
Journal:  Nano Today       Date:  2014-12-01       Impact factor: 20.722

6.  Cancer cell spheroids as a model to evaluate chemotherapy protocols.

Authors:  Federico Perche; Vladimir P Torchilin
Journal:  Cancer Biol Ther       Date:  2012-08-15       Impact factor: 4.742

7.  A novel individual-cell-based mathematical model based on multicellular tumour spheroids for evaluating doxorubicin-related delivery in avascular regions.

Authors:  Jiali Liu; Fangrong Yan; Hongzhu Chen; Wenjie Wang; Wenyue Liu; Kun Hao; Guangji Wang; Fang Zhou; Jingwei Zhang
Journal:  Br J Pharmacol       Date:  2017-07-30       Impact factor: 8.739

Review 8.  Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?

Authors:  Yuko Nakamura; Ai Mochida; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2016-09-02       Impact factor: 4.774

9.  Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.

Authors:  Bonnie L Hylander; Arindam Sen; Sarah H Beachy; Rose Pitoniak; Soumya Ullas; John F Gibbs; Jingxin Qiu; Joshua D Prey; Gerald J Fetterly; Elizabeth A Repasky
Journal:  J Control Release       Date:  2015-09-03       Impact factor: 9.776

10.  Therapeutic nanosystems for oncology nanomedicine.

Authors:  A S Gonçalves; A S Macedo; E B Souto
Journal:  Clin Transl Oncol       Date:  2012-07-27       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.